About
Michael Grissinger joined Adicet Bio's board in April 2025. He spent 22 years at Johnson & Johnson before retiring in 2018, serving in senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A, and leading the Immunology Therapeutic Area Business Development and Licensing Group.
Prior to Johnson & Johnson he spent 12 years at Ciba-Geigy AG in finance, marketing and business development roles. He holds a B.Sc. in Chemistry from Juniata College and an MBA from Temple University's Fox School of Business.
Roles
Adicet Bio, Inc.
Director · Current role
2025–present
Johnson & Johnson
VP & Head of Worldwide Pharmaceutical Licensing; VP & Head of Worldwide Pharmaceutical Corporate Development and M&A · Spent 22 years at the company and retired in 2018; also led the Immunology Therapeutic Area Business Development and Licensing Group.
—
Ciba-Geigy AG
Finance, marketing and business development roles · Spent 12 years at the company prior to joining Johnson & Johnson.
—
Akari Therapeutics, Plc
Board member
2018-2024
resTORbio
Board member · Served from November 2018 until the completion of the merger in September 2020.
2018-2020
External Roles
Aprea Therapeutics, Inc.
Board member
—
Envisagenics, Inc.
Board member
—
AnaCardio AB
Board member
—
NephroDI Therapeutics, Inc.
Board member
—
Director Compensation
FY 2025Fees earned or paid in cash
$31,772
Option awards
$27,859
Total
$59,631
Also at Adicet Bio, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.